Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/05/15/2882910/0/en/Plus-Therapeutics-Reports-First-Quarter-2024-Financial-Results-and-Recent-Business-Highlights.html
https://www.globenewswire.com/news-release/2024/05/13/2880318/0/en/Plus-Therapeutics-to-Announce-First-Quarter-Financial-Results-and-Host-Conference-Call-on-May-15-2024.html
https://www.globenewswire.com/news-release/2024/05/09/2878977/0/en/Plus-Therapeutics-Provides-Highlights-Regarding-Leptomeningeal-Metastases-Acquisition-and-Topline-Clinical-Trial-Data-on-the-FORESEE-Trial.html
https://www.globenewswire.com/news-release/2024/05/08/2878363/0/en/Plus-Therapeutics-to-Host-Investor-Call-to-Discuss-Leptomeningeal-Cancer-Related-Acquisition-and-Topline-Clinical-Trial-Data-from-the-FORESEE-Trial.html
https://www.globenewswire.com/news-release/2024/05/06/2875716/0/en/Plus-Therapeutics-Announces-Private-Placement-Financing-of-up-to-18-Million.html
https://www.globenewswire.com/news-release/2024/04/22/2866728/0/en/Plus-Therapeutics-Receives-3-Million-Award-Recommendation-from-the-United-States-Department-of-Defense.html
https://www.globenewswire.com/news-release/2024/03/27/2853110/0/en/Plus-Therapeutics-to-Present-at-the-National-Comprehensive-Cancer-Network-Annual-Conference.html
https://www.globenewswire.com/news-release/2024/03/25/2851568/0/en/Plus-Therapeutics-Announces-Validation-Clinical-Implementation-of-CSF-01-Leptomeningeal-Cancer-Cell-Diagnostic.html
https://www.globenewswire.com//news-release/2024/03/11/2843624/0/en/Plus-Therapeutics-Completes-Dosing-in-Cohort-5-of-ReSPECT-LM-Phase-1-Trial-of-Rhenium-186Re-Obisbemeda-in-Leptomeningeal-Metastases.html
https://www.globenewswire.com//news-release/2024/03/05/2840902/0/en/Plus-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Business-Highlights.html